Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Duchenne muscular dystrophy
Pharma
FDA limits Elevidys gene therapy to ambulatory Duchenne patients
The Elevidys label now includes a boxed warning and a new “limitation of use” in addition to the removal of the non-ambulatory indication.
Angus Liu
Nov 14, 2025 3:20pm
Sarepta, despite key trial flop, will seek full nod for DMD meds
Nov 4, 2025 7:56am
Untangling Sarepta’s gene therapy fallout
Aug 1, 2025 9:07am
FDA investigates 3rd death of an Elevidys patient
Jul 28, 2025 11:06am
2nd patient dies after Sarepta's DMD gene therapy Elevidys
Jun 16, 2025 10:58am
Roche's Vabysmo will rise above Eylea biosim threat, exec says
Oct 23, 2024 11:24am
